Rationale for Treatment of mNSCLC with Immune Checkpoint Inhibitors

Data from CheckMate 9LA trial further support the use of nivolumab plus ipilimumab and chemotherapy as an efficacious first-line treatment option for patients with metastatic NSCLC, says David P. Carbone, MD, PhD.

Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.

Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.

News from KEYNOTE-671 in early-stage non–small cell lung cancer provides more evidence to support the FDA approval application for perioperative pembrolizumab.

Amivantamab elicited an objective response rate of 37% per investigator assessment, with a median duration of response of 12.5 months, according to long-term data from the CHRYSALIS trial.

The primary end point of overall survival was not met in the phase 3 SAPPHIRE study of sitravatinib plus nivolumab in patients with advanced non-squamous non–small cell lung cancer.